Arcellx, Inc. entered into an amendment to its Collaboration and License Agreement with Kite Pharma, Inc., exercising its option to negotiate a license for Arcellx's ARC-SparX program and expanding the collaboration for CART-ddBCMA, receiving an upfront cash payment of $85 million and potential milestone payments.